Pokrok v léčbě karcinomu plic
| Title in English | Advances in the treatment of lung cancer |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Proceedings |
| Conference | Aktuality z vnitřního lékařství 2016 |
| MU Faculty or unit | |
| Citation | |
| Field | Pneumology |
| Keywords | lung cancer; non-small-cell lung cancer; small-cell lung cancer; chemotherapy; immunotherapy |
| Description | Treatment of non-small-cell lung cancer (NSCLC) has made impressive advances in recent years. Use of biologies and immunotherapy in NSCLC has improved survival rates of patients with inoperable locally advanced and metastatic NSCLC. Agents specifically targeted at processes within tumor cells have been shown to be particularly useful in adenocarcinomas. Once the diagnosis has been established, it is essential to make as accurate as possible morphological diagnosis to be followed, if indicated, by genetic testing. Immunotherapeutics have also been shown to be effective in squamous NSCLC. Regarding small-cell lung cancer (SCLC), our understanding of driver mutations and mechanisms is still limited. Currently, the standard chemotherapeutic regimen with SCLC continues to be combinations of etoposide and cisplatin or etopo-side and carboplatin. Radiotherapy makes an integral part of treatment of NSCLC and SCLC. |